Eli Lilly revenue growth and market activity

Eli Lilly and Company has experienced significant revenue growth, reporting $23 billion for the second quarter, a 48% year-over-year increase. This growth is primarily attributed to high demand for its GLP-1 metabolic therapies, specifically tirzepatide marketed under the names Mounjaro and Zepbound, which are used for diabetes and weight management.

Regulatory developments include the FDA expanding Mounjaro’s approved uses to include reducing the risk of major adverse cardiovascular events in high-risk adults with type 2 diabetes.

Institutional investment in the company has shown varied activity. While GTS Securities LLC reduced its stake by 52.6%, other firms such as Alyeska Investment Group L.P. and Bluefin Capital Management LLC established new positions. Additionally, Putnam Investment Management Co., Wedbush Securities Inc., and Rational Advisors Inc. increased their holdings. Institutional investors and hedge funds currently hold approximately 82.53% of the company’s stock.